|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JP2518911B2
(ja)
|
1987-10-23 |
1996-07-31 |
森永乳業株式会社 |
ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5866114A
(en)
|
1992-06-09 |
1999-02-02 |
Chiron Corporation |
Crystallization of M-CSFα
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999029345A1
(en)
|
1997-12-05 |
1999-06-17 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
WO2000025803A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparations
|
|
JP4307775B2
(ja)
|
1999-10-28 |
2009-08-05 |
ゼイェトホサイン・アハリネヤート |
Ｃｓｆ−１インヒビターの使用
|
|
AU1759501A
(en)
|
1999-11-08 |
2001-06-06 |
Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
AU2002314495A1
(en)
|
2001-06-20 |
2003-01-02 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
CA2505994A1
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
US7807389B2
(en)
|
2003-03-14 |
2010-10-05 |
University Of Rochester |
Methods and compositions related to joint inflammation diseases
|
|
WO2005040395A1
(en)
|
2003-10-22 |
2005-05-06 |
Keck Graduate Institute |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
EP1706137A2
(en)
|
2004-01-21 |
2006-10-04 |
Chiron Corporation |
M-csf muteins and uses thereof
|
|
CA2565974A1
(en)
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
WO2006012451A2
(en)
|
2004-07-22 |
2006-02-02 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
ATE454455T1
(de)
|
2005-01-27 |
2010-01-15 |
Five Prime Therapeutics Inc |
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
RU2008123518A
(ru)
|
2005-11-10 |
2009-12-20 |
Ресептор Байолоджикс, Инк. (Us) |
Способы получения изоформ рецепторов и лигандов
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
CA2634945A1
(en)
|
2005-12-22 |
2007-10-25 |
Novartis Ag |
Soluble human m-csf receptor and uses thereof
|
|
RU2470665C2
(ru)
|
2006-01-05 |
2012-12-27 |
Новартис Аг |
Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
|
|
RS56600B1
(sr)
|
2006-04-19 |
2018-02-28 |
Novartis Ag |
6-o-supstituisana jedinjenja benzoksazola i benzotiazola i postupci inhibicije csf-1r signalinga
|
|
WO2008061013A2
(en)
|
2006-11-10 |
2008-05-22 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
EP2089049A4
(en)
|
2006-11-17 |
2011-11-16 |
Biogen Idec Inc |
SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
|
|
US7919594B2
(en)
|
2007-02-14 |
2011-04-05 |
Vaccinex, Inc. |
Human anti-CD100 antibodies
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
|
WO2008150383A1
(en)
|
2007-05-30 |
2008-12-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Csf-1r mutants
|
|
CN101802008B
(zh)
|
2007-08-21 |
2015-04-01 |
安美基公司 |
人类c-fms抗原结合蛋白
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
CA2702699A1
(en)
|
2007-10-18 |
2009-04-23 |
Novartis Ag |
Csf-1r inhibitors compositions, and mthods of use
|
|
JP2011502266A
(ja)
|
2007-10-31 |
2011-01-20 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｆｍｓ治療に対する応答を評価するバイオマーカー
|
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
AU2009224955B2
(en)
|
2008-03-14 |
2012-08-09 |
Transgene S.A. |
Antibody against the CSF-1 R
|
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
EP2313411A1
(en)
|
2008-06-10 |
2011-04-27 |
Plexxikon, Inc. |
5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor
|
|
WO2010062399A2
(en)
|
2008-11-26 |
2010-06-03 |
Five Prime Therapeutics, Inc. |
Csf1r extracellular domain fusion molecules and treatments using same
|
|
US8183207B2
(en)
|
2008-11-26 |
2012-05-22 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
|
|
MA33975B1
(fr)
|
2009-11-06 |
2013-02-01 |
Plexxikon Inc |
Composés et méthodes de modulation des kinases et leurs indications d'emploi
|
|
PT2949670T
(pt)
|
2009-12-10 |
2019-05-20 |
Hoffmann La Roche |
Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
|
|
NZ601376A
(en)
|
2009-12-21 |
2014-03-28 |
Array Biopharma Inc |
Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
|
|
WO2011107553A1
(en)
|
2010-03-05 |
2011-09-09 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
CN107011438B
(zh)
|
2010-05-04 |
2020-11-20 |
戊瑞治疗有限公司 |
结合csf1r的抗体
|
|
TW201307845A
(zh)
|
2010-12-13 |
2013-02-16 |
Novartis Ag |
預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
|
|
US9139652B2
(en)
|
2011-10-21 |
2015-09-22 |
Transgene Sa |
Method for increasing M1 macrophages in a patient
|
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
JP5865995B2
(ja)
*
|
2012-03-26 |
2016-02-17 |
日本ケミファ株式会社 |
骨・軟部に発生する巨細胞性腫瘍または軟骨肉腫の予防または治療剤
|
|
US20130302322A1
(en)
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
AU2012374617B2
(en)
|
2012-05-11 |
2015-09-17 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|